Methionine
drugOn this page
Also known as L-methionineMetioninaNSC-22946METHOINE(L)-MethionineL-Methionine methylsulfonium iodide
Summary
Methionine (CHEMBL42336) is an approved small-molecule nutraceutical (ATC V03AB26); indicated across 11 conditions including obstructive jaundice and noise induced hearing loss.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AB26
- Indications: 11 conditions
- Clinical trials: 13
- Chemistry: 149.21 Da · C5H11NO2S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL42336 |
| Name | Methionine |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 6137 |
| ChEBI | CHEBI:16643 |
| ATC | V03AB26 |
| Molecular formula | C5H11NO2S |
| Molecular weight | 149.21 |
| InChIKey | FFEARJCKVFRZRR-BYPYZUCNSA-N |
SMILES: CSCC[C@@H](C(=O)O)N
IUPAC name: (2S)-2-amino-4-methylsulfanylbutanoic acid
ChEBI definition: The L-enantiomer of methionine.
Pharmacological roles (ChEBI): nutraceutical, micronutrient, antidote to paracetamol poisoning.
Other ChEBI roles (chemical / environmental): human metabolite, mouse metabolite.
Also known as: L-methionine, Methionine, Metionina, NSC-22946, methionine, L-Methionine, METHIONINE, METHOINE, (L)-Methionine, L-METHIONINE, L-Methionine methylsulfonium iodide
Parent form; salt/anhydrous children: CHEMBL1770614, CHEMBL2106977
Patent coverage: 230,705 distinct patent families (647,509 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: S-ribosylhomocysteine lyase.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| obstructive jaundice | 3 | MONDO:0006874 | EFO:1001068 |
| noise induced hearing loss | 3 | MONDO:0013098 | EFO:1001254 |
| rhabdomyosarcoma | 2 | MONDO:0005212 | EFO:0002918 |
| chronic hepatitis C virus infection | 2 | MONDO:0005354 | EFO:0004220 |
| ependymoma | 2 | MONDO:0016698 | EFO:1000028 |
| craniopharyngioma | 2 | MONDO:0018907 | EFO:1000209 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
| pulmonary alveolar proteinosis | 1 | MONDO:0001437 | MONDO:0001437 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00032695 | PHASE3 | COMPLETED | Treatment of AIDS Vacuolar Myelopathy With Methionine |
| NCT02824419 | PHASE2/PHASE3 | UNKNOWN | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis |
| NCT03418935 | PHASE3 | COMPLETED | Remaxol® in Mechanical Jaundice of Non-malignant Origin |
| NCT00840047 | PHASE2 | ACTIVE_NOT_RECRUITING | Methionine PET/CT Studies In Patients With Cancer |
| NCT03887169 | PHASE1/PHASE2 | COMPLETED | Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. |
| NCT05511714 | Not specified | AVAILABLE | Expanded Access [11C] Methionine PET Imaging |
| NCT07465367 | Not specified | NOT_YET_RECRUITING | Methionine for CaPhos Stone |
| NCT00253760 | Not specified | COMPLETED | Metabolic Analysis in Human Sulfur Amino Acid Deficiency |
| NCT00253773 | Not specified | COMPLETED | Metabolic Effects of Chemical Interactions in Toxicity |
| NCT00597246 | Not specified | COMPLETED | Imaging Brain Tumors With FACBC and Methionine |
| NCT02566434 | Not specified | COMPLETED | Methionine Tolerance in Healthy Human Adults |
| NCT03180775 | Not specified | UNKNOWN | Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity |
| NCT04326322 | Not specified | COMPLETED | Methionine Requirements During Healthy Human Pregnancy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: obstructive jaundice, noise induced hearing loss